One example is the multikinase inhibitor, Nexavar, used against renal cell and hepatocellular carcinoma (Llovet et al., 2008; Roberts, 2008), although it is unclear to what extent the efficacy of Nexavar towards these cancers is related to the inhibition of C-Raf, B-Raf, or VEGFR (Downward, 2003; Baines et al., 2011). This evidence concerns the gene RAF1 and cancer.